Emergent BioSolutions (EBS) Gains from Sales and Divestitures (2011 - 2018)

Emergent BioSolutions' Gains from Sales and Divestitures history runs 8 years deep, the most recent figure standing at $427610.0 for Q4 2018.

• In Q4 2018, Gains from Sales and Divestitures rose 0.89% year-over-year to $427610.0; the TTM figure through Dec 2018 stood at $427610.0 (up 0.89% YoY), while the FY2018 annual figure was $427610.0, up 0.89% from the prior year.
• Gains from Sales and Divestitures was $427610.0 for Q4 2018 at Emergent BioSolutions, up from $423840.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $427610.0 in Q4 2018 to a low of $298489.0 in Q1 2014.
• Historically, Gains from Sales and Divestitures has averaged $384188.2 across 5 years, with a median of $403992.0 in 2017.
• The sharpest annual moves came in 2015 and 2016: Gains from Sales and Divestitures increased 19.5% in 2015, then slipped 1.0% in 2016.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $361010.0 in 2014, then rose by 17.04% to $422515.0 in 2015, then dropped by 0.45% to $420599.0 in 2016, then increased by 0.77% to $423840.0 in 2017, then grew by 0.89% to $427610.0 in 2018.
• The last three Gains from Sales and Divestitures figures came in at $427610.0 (Q4 2018), $423840.0 (Q4 2017), and $413752.0 (Q3 2017), per Business Quant data.